Skip to main content
. 2009 Feb 18;2:1–15.

Table 1.

Initial phase II trials of bevacizumab in metastatic colorectal cancer

Phase II studies Chemotherapy regimen n Time to progression (months) Response rate Median survival (months)
Kabbinavar et al47 5-FU/LV 36 5.2 6 (17%) 13.8
5-FU/LV + BV 5 mg/kg 35 9 14 (40%) 21.5
5-FU/LV + BV 10 mg/kg 33 7.2 8 (24%) 16.1
Kabbinavar et al57 5-FU/LV 105 5.5 15.2% 12.9
5-FU/LV + BV 5 mg/kg 104 9.2 26% 16.6

Abbreviation: BV, bevacizumab.